Feeds:
Posts
Comments

Posts Tagged ‘nexium’

*****

TODAY’S NEWS

Little Pricey Pill: A BusinessWeek slam on the Nexium approach to me-too drug marketing.

Pfizer and the Neurontin marketing fraud: $142M please.

Head-to-head MS drug effectiveness studies coming. This should be interesting.

RECOMMENDED

Video storytelling – Impactiviti’s vendor/partners have just what you need for directing and producing corporate videos.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

The latest Impactiviti Connection e-newsletter is up! You can subscribe here.

PLUS

But Are We Communicating? My rant on pharma communications, regulations, and social media.

JUST FOR FUN

Top 100 April Fools Pranks. ‘Cause it’s about that time…

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

Is Schering‘s contraceptive NuvaRing dangerous.? This article raises the question. My take – it’s always a yellow light for me when I see a journalistic heart-string approach based on an isolated (and unproven) incident. What sells newspapers is not the same as science.

Does this really need to be treated as a “new drug”? I have some real problems with this approach – AstraZeneca files NDA for Nexium + low-dose aspirin. Umm, folks, this is not a scientific advance. And patients are fully able to take an aspirin without needing an expensive purple coating over it…

BusinessWeek gives its list of the 10 most promising new drugs (due out over next 2 years). Fairly interesting if you’ve not been keeping up with pipelines – not much new information here, however.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Read Full Post »